Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2b Study of ZEN003694 in Combination With Enzalutamide Versus Enzalutamide Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT04986423 is registered in ClinicalTrials.gov with Zenith Epigenetics as lead sponsor.

NCT NCT04986423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04986423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2b Study of ZEN003694 in Combination With Enzalutamide Versus Enzalutamide Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Zenith Epigenetics
Phase
Phase 2
Overall status
Recruiting
Start date
September 8, 2021
Completion date
June 30, 2027
Enrollment
200 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer